Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
January 6, 2012 | Oncology Practice
Author and Disclosure Information
SAN ANTONIO – Dr. William J. Gradishar and Dr. Hope S. Rugo, associate editors of The Oncology Report, discuss fulvestrant and anastrozole as first-line therapy for postmenopausal women with hormone receptor-positive breast cancer.